Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1611-1618

  Pei, Sung Nan ^a   Chen, Chien Hung ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Chemotherapy; Hepatitis B virus; Hepatitis B virus reactivation; Lymphoma; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RITUXIMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DISEASE COURSE; DRUG CYTOTOXICITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; LYMPHOMA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMIC THERAPY; VIRUS REACTIVATION; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; VIROLOGY; VIRUS ACTIVATION;

ANTINEOPLASTIC AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LYMPHOMA; RISK FACTORS; RITUXIMAB; VIRUS ACTIVATION;

EID: 84928988291     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.964699     Document Type: Review

References (90)

1. Lee W M. H epatitis B virus infection. N Engl J Med 1 997; 3 37: 1733-1745.
2. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
3. Wang J T, Wang T H, Sheu J C, et al. D etection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis 1991; 163: 397-399.
4. Shih LN, Sheu JC, Wang JT, et al. Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction. J Med Virol 1990; 32: 257-260.
5. Marignani M, Gigante E, Begini P, et al. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol 2012; 4: 37-45.
6. Leung N W, Tam J S, Lau G T, et al. H epatitis B virus DNA in peripheral blood leukocytes. A comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer 1994; 73: 1143-1148.
7. Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients ' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108.
8. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-657.
9. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749.
10. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy- Associ. hepatitis B reactivation in non-Hodgkin ' s lymphoma: A randomized trial. Hepatology 2008; 47: 844-853.
11. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113: 3147-3153.
12. Cucuianu A, Patiu M, Duma M, et al. Hepatitis B and C virus infection in Romanian non-Hodgkin ' s lymphoma patients. Br J Haematol 1999; 107: 353-356.
13. Talamini R, Montella M, Crovatto M, et al. Non-Hodgkin ' s lymphoma and hepatitis C virus: A case-control study from northern and southern Italy. Int J Cancer 2004; 110: 380-385.
14. Kang J, Cho JH, Suh CW, et al. High prevalence of hepatitis B and hepatitis C virus infections in Korean patients with hematopoietic malignancies. Ann Hematol 2011; 90: 159-164.
15. Chen M H, Hsiao L T, Chiou T J, et al. H igh prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin ' s lymphoma. Ann Hematol 2008; 87: 475-480.
16. Alexopoulos C G, Vaslamatzis M, Hatzidimitriou G. P revalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 1999; 81: 69-74.
17. Pioltelli P, Gargantini L, Cassi E, et al. Hepatitis C virus in non-Hodgkin ' s lymphoma. A reappraisal after a prospective case-control study of 300 patients. Lombart Study Group of HCV-Lymphoma. Am J Hematol 2000; 64: 95-100.
18. Kim JH, Bang YJ, Park BJ, et al. Hepatitis B virus infection and B-cell non-Hodgkin ' s lymphoma in a hepatitis B endemic area: A case-control study. Jpn J Cancer Res 2002; 93: 471-477.
19. Iwata H, Matsuo K, Takeuchi K, et al. High incidences of malignant lymphoma in patients infected with hepatitis B or hepatitis C virus. Haematologica 2004; 89: 368-370.
20. Takai S, Tsurumi H, A ndo K, et al. P revalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005; 74: 158-165.
21. Amin J, Dore GJ, O' Connell DL, et al. Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study. J Hepatol 2006; 45: 197-203.
22. Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin ' s lymphoma. Haematologica 2006; 91: 554-557.
23. Lim ST, Fei G, Quek R, et al. The relationship of hepatitis B virus infection and non-Hodgkin ' s lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol 2007; 79: 132-137.
24. Sonmez M, Bektas O, Yilmaz M, et al. The relation of lymphoma and hepatitis B virus/hepatitis C virus infections in the region of East Black Sea, Turkey. Tumori 2007; 93: 536-539.
25. Ulcickas Yood M, Quesenberry CP Jr, Guo D, et al. Incidence of non-Hodgkin ' s lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007; 46: 107-112.
26. Park SC, Jeong SH, Kim J, et al. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin ' s lymphoma in Korea. J Med Virol 2008; 80: 960-966.
27. Wang F, Xu RH, Luo HY, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 2008; 8: 115.
28. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927-1932.
29. Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 2010; 149: 3-13.
30. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
31. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
32. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69.
33. Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89: 255-261.
34. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611.
35. Koo YX, Tan DS, Tan IB, et al. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010; 116: 115-121.
36. Matsue K, Kimura SI, Takanashi Y, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010; 116: 4769-4776.
37. Hsu C, Tsou H H, Lin S J, et al. C hemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology 2014; 59: 2092-2100.
38. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab- Associ. hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772.
39. Zurawska U, Hicks LK, Woo G, et al. Hepatitis B virus screening before chemotherapy for lymphoma: A cost-effectiveness analysis. J Clin Oncol 2012; 30: 3167-3173.
40. Hay AE, Meyer RM. Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness. J Clin Oncol 2012; 30: 3155-3157.
41. Yeo W, Chan P K, Hui P, et al. H epatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study. J Med Virol 2003; 70: 553-561.
42. Hwang J P, Lok A S. M anagement of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014; 11: 209-219.
43. Lok A S, Liang R H, Chiu E K, et al. R eactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188.
44. Liao CA, Lee CM, Wu HC, et al. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin' s lymphoma. Br J Haematol 2002; 116: 166-169.
45. Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-1328.
46. Yeo W, Chan P K, Zhong S, et al. F requency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
47. Dai M S, Chao T Y, Kao W Y, et al. D elayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769-774.
48. Yeo W, Zhong S, Chan P K, et al. S equence variations of precore/ core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J Viral Hepat 2000; 7: 448-458.
49. Zhong S, Yeo W, Schroder C, et al. H igh hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004; 11: 55-59.
50. European Association For The Study Of The Liver. E ASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
51. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008; 2: 263-283.
52. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
53. Liang RH, Lok AS, Lai CL, et al. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990; 8: 261-270.
54. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin' s lymphoma. Blood 1997; 90: 2188-2195.
55. Czuczman M S, Grillo-Lopez A J, White C A, et al. T reatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
56. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin ' s lymphoma. Ann Oncol 1999; 10: 655-661.
57. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin ' s lymphoma. J Clin Oncol 2001; 19: 389-397.
58. Wilson W H, Gutierrez M, O' C onnor P, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose- Adjusted EPOCH-R. Semin Oncol 2002; 29: 41-47.
59. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
60. Pfreundschuh M, Trumper L, Osterborg A, et al. C HOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabTh era International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
61. Dong H J, Ni L N, Sheng G F, et al. R isk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximabchemotherapy: A meta- Analysis. J Clin Virol 2013; 57: 209-214.
62. Chen XQ, Peng JW, Lin GN, et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 2012; 29: 1237-1241.
63. He YF, Li YH, Wang FH, et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008; 87: 481-485.
64. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
65. Niscola P, Del Principe MI, Maurillo L, et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 2005; 19: 1840-1841.
66. WesthoffTH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
67. Sarrecchia C, Cappelli A, A iello P. H BV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189-191.
68. Sera T, Hiasa Y, Michitaka K, et al. A nti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006; 45: 721-724.
69. Yamagata M, Murohisa T, Tsuchida K, et al. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma 2007; 48: 431-433.
70. Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin ' s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627-629.
71. Law JK, Ho JK, Hoskins PJ, et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigennegative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085-1089.
72. Fukushima N, Mizuta T, Tanaka M, et al. R etrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009; 20: 2013-2017.
73. Francisci D, Falcinelli F, Schiaroli E, et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010; 38: 58-61.
74. Hanbali A, Khaled Y. Incidence of hepatitis B reactivation following rituximab therapy. Am J Hematol 2009; 84: 195.
75. Tsutsumi Y, Shigematsu A, Hashino S, et al. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin ' s lymphoma in Hokkaido. Ann Hematol 2009; 88: 375-377.
76. Evens A M, Jovanovic B D, Su Y C, et al. R ituximab- Associ. hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta- Analysis and examination of FDA safety reports. Ann Oncol 2011; 22: 1170-1180.
77. Targhetta C, Cabras M G, Mamusa A M, et al. H epatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo-or chemo-immune therapy. Haematologica 2008; 93: 951-952.
78. Sugauchi F, Tanaka Y, Kusumoto S, et al. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol 2011; 83: 412-418.
79. Kusumoto S, Tanaka Y, Ueda R, et al. R eactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 2011; 46: 9-16.
80. Ceccarelli L, Salpini R, Sarmati L, et al. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximabcontaining therapy. J Infect 2012; 65: 180-183.
81. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
82. Chew E, Th ursky K, Seymour JF. Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis-the need for continued vigilance. Leuk Lymphoma 2014; 55: 938-939.
83. Khokhar OS, Farhadi A, McGrail L, et al. Oncologists and hepatitis B: A survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 2009; 55: 69-75.
84. Tran TT, Rakoski MO, Martin P, et al. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Th er 2010; 31: 240-246.
85. Lee RS, Bell CM, Singh JM, et al. Hepatitis B screening before chemotherapy: A survey of practitioners ' knowledge, beliefs, and screening practices. J Oncol Pract 2012; 8: 325-328.
86. Marignani M, Marzano A, Begini P, et al. Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. Leuk Lymphoma 2014; 55: 2564-2571.
87. Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010; 28: 3199-3202.
88. Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597-1603.
89. Borentain P, Colson P, Coso D, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAgnegative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 2010; 17: 807-815.
90. Pei S N, Ma M C, Wang M C, et al. A nalysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012; 91: 1007-1012.